—

GlaxoSmithKline PLC ADR(GSK)— 同業公司組

數據截至2026-09-24 — 評分每個交易日晚間重新計算。分組標準=首先為共同的Closelook指數成分,其次為產業。Closelook研究日記,不構成投資建議。

GlaxoSmithKline PLC ADR的Closelook綜合評分為53/100,在同業公司組內排名第9位(共11家)——組內評分最高的是Halozyme Therapeutics Inc(74/100)。

名稱綜合動能品質估值訊號距52週高點
GSK GlaxoSmithKline PLC ADR53347958info17.4%
LLY Eli Lilly and Company64719128watch11%
SAN.PA Sanofi SA56356861watch15.3%
NVO Novo Nordisk A/S55308674bear38.3%
AMGN Amgen Inc54718443bull9.2%
GRF.MC Grifols S.A.48444380info26.4%
VIRP.PA Virbac SA48245461warn22.1%
HALO Halozyme Therapeutics Inc74969445ok1.4%
DXCM DexCom Inc66858036neutral5.2%
ARGX argenx NV ADR64747327ok10.3%
ONC BeiGene, Ltd.64796332ok6.6%

評分為Closelook全部涵蓋範圍內的相對讀數——方法論詳見公司評分說明。訊號燈來自每日夜間訊號看板。

FAQ · from the current data · as of 2026-09-24

Quick answers

GlaxoSmithKline PLC ADR在Closelook涵蓋範圍內的同業公司有哪些?

分組首先根據共同的Closelook指數成分,其次根據產業:Eli Lilly and Company (LLY)、Sanofi SA (SAN.PA)、Novo Nordisk A/S (NVO)、Amgen Inc (AMGN)、Grifols S.A. (GRF.MC)、Virbac SA (VIRP.PA)、Halozyme Therapeutics Inc (HALO)、DexCom Inc (DXCM)等。

GSK相對同業公司的評分如何?

GlaxoSmithKline PLC ADR的綜合評分為53/100,組內排名第9位(共11家),截至2026-09-24;組內最高綜合評分為Halozyme Therapeutics Inc(74/100)。Closelook評分為研究日記讀數,不構成評等或投資建議。

Related in the Closelook universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.